HUTCHMED's Sovleplenib Clears Critical Phase III Hurdle for Warm Autoimmune Hemolytic Anemia Treatment

HUTCHMED (China) Limited (HCM) achieved a major milestone this week as its investigational drug sovleplenib successfully hit the primary endpoint in a pivotal Phase III trial targeting warm autoimmune hemolytic anemia (wAIHA) in China. The market responded positively, with HCM shares climbing $0.38 to $13.75 during regular trading and extending gains to $14.02 in after-hours activity.

What’s Behind the Clinical Win

The ESLIM-02 registration trial demonstrated that sovleplenib achieved a durable hemoglobin response rate measured between weeks 5 and 24 of treatment. This outcome is particularly significant for wAIHA, a rare autoimmune blood disorder where patients’ own antibodies attack and destroy red blood cells, causing severe anemia.

Sovleplenib works by inhibiting spleen tyrosine kinase (Syk), a protein that plays a central role in immune cell signaling. Syk sits at the intersection of B-cell receptor and Fc receptor pathways—key mechanisms in autoimmune diseases and certain blood cancers. By targeting this pathway, the drug effectively dampens the aberrant immune response responsible for wAIHA.

Timeline to Market and Pipeline Expansion

HUTCHMED plans to file a New Drug Application with China’s National Medical Products Administration (NMPA) during the first half of 2026 based on these Phase III results. This positions sovleplenib to become a treatment option for a patient population with limited therapeutic choices.

Beyond wAIHA, sovleplenib is simultaneously advancing in immune thrombocytopenia (ITP), another autoimmune blood disorder. The company already published positive Phase III data from the ESLIM-01 trial in ITP patients in The Lancet Haematology, with an NDA resubmission for second-line ITP treatment also planned for H1 2026.

Global Rights and Strategic Position

HUTCHMED retains worldwide rights to sovleplenib, maintaining full control over its development and commercialization across all territories and indications—a strategic advantage in a competitive immunology landscape.

The Phase III success in warm autoimmune hemolytic anemia validates both the drug’s mechanism and the company’s clinical execution, setting the stage for multiple regulatory submissions within the next 12 months.